## **GalliaPharm®** Radionuclide Generator



### GalliaPharm<sup>®</sup> <sup>68</sup>Ge/<sup>68</sup>Ga Generator

Cyclotron-independent production of the positron emitter <sup>68</sup>Gallium

### Description

The GalliaPharm<sup>®</sup> <sup>68</sup>Ge/<sup>68</sup>Ga Radionuclide Generator from Eckert & Ziegler Radiopharma GmbH is a pharmaceutical product for obtaining the positron emitter <sup>68</sup>Gallium, independent of a cyclotron.

GalliaPharm<sup>®</sup> is a closed system consisting of pharmacopoeia grade borosilicate glass column containing a titanium dioxide bed on which <sup>68</sup>Ge is adsorbed. <sup>68</sup>Ga is continuously produced by decay of its radioactive parent <sup>68</sup>Ge and is eluted with sterile ultrapure 0,1 mol/l hydrochloric acid. GalliaPharm<sup>®</sup> is available with the following activities: 740 MBq, 1110 MBq, 1480 MBq and 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi).

### **Advantages**

The GalliaPharm® is produced under GMP conditions ensuring highest quality standards and is designed to minimize both <sup>68</sup>Ge breakthrough and metal impurities. No metals are used within the closed system. All components are compliant with the monographs of the European Pharmacopeia (if available) or their suitability for the respective application has been tested otherwise.

### **Marketing Authorization**

A <sup>68</sup>Ge/<sup>68</sup>Ga generator is regarded as a drug product in Europe and requires full registration to receive marketing authorization. The sterile and GMP compliant GalliaPharm<sup>®</sup> has been registered in 17 European countries and Canada. The sterile ultrapure 0,1 mol/l hydrochloric acid provided by Eckert & Ziegler Radiopharma GmbH is essential part of the registration and must not be replaced by any substitute product.

In the USA a <sup>68</sup>Ge/<sup>68</sup>Ga generator is regarded as a drug substance.

### Output

In practice, the generator requires seven hours to achieve full yield after being eluted. 90 % yield will be achieved after four hours. The output will decrease with decay of the <sup>68</sup>Ge parent.

### **Quality Control Process**

Every GalliaPharm<sup>®</sup> has to pass several tests, mentioned in the 'Gallium (<sup>68</sup>Ga) chloride solution for Radiolabelling' monograph of the European Pharmacopoeia, before delivery. Additionally, Eckert & Ziegler Radiopharma GmbH also tests sterility of the eluate. Finally, GalliaPharm<sup>®</sup> is released by a qualified person.

### The GalliaPharm<sup>®</sup> eluate complies with the following specifications (excerpt):

Test parameter	Specification
Appearance	Clear colorless solution
Identity 68Ga	Half-life 62–74 min
Content	> 60 % of nominal activity
Chemical impurity	Fe < 10 μg / GBq Zn < 10 μg / GBq
Radionuclidic impurity (y-emitting impurities)	< 0,001 % of nominal activity
Radiochemical purity	> 95 % free <sup>68</sup> Ga <sup>3+</sup>
рН	0,5–2,0
Microbiological quality	Sterile
Bacterial endotoxins	< 20 EU / ml



# **GalliaPharm®**

### GalliaPharm<sup>®</sup> Shelf-Life

Expected shelf-life of GalliaPharm<sup>®</sup> is dependent upon several factors such as frequency of use, volume of elution and others. The useful life of the generator has been investigated in a long-term study and may vary from country to country. A shelf-life of 12 months is justified when used according to the Summary of Product Characteristics (SmPC). No additional testing for <sup>68</sup>Ge breakthrough will be necessary.

#### **Technical Specifications**

General Data		
Dimensions (W x D x H)	132 x 133 x 230 mm	
Weight	14 kg	
Recommended time between two elutions	4 hours	
Number of possible elutions	> 550 elutions	
68Ge breakthrough	Not more than 0,001 %	
Eluent*	Sterile ultrapure 0,1 mol/l hydrochloric acid	
Elution Speed	2,0 ml/min	
Available activities	740 MBq, 1110 MBq, 1480 MBq, 1850 MBq (20 mCi, 30 mCi, 40 mCi, 50 mCi)	
Decay Characteristics		
Half-life	<sup>68</sup> Ge: 271 days <sup>68</sup> Ga: 68 minutes	
Radiation type	Positrons: Photons:	up to 1,90 MeV from <sup>68</sup> Ga daughter; 89 % abundance 0,511 MeV positron annihilation radiation; 178 % abundance 1,077 MeV gamma radiation; 3,2 % abundance
Order Information		
Delivery Time	Upon request	
Additional Information		
Countries of registration	GalliaPharm <sup>®</sup> has been registered as a medicinal product in the following 17 European countries (AT, BE, CZ, DE, DK, ES, FI, FR, IE, IT, LV, NL, NO, PL, SE, SK, UK) and Canada. Type II DMF in the USA: #28741	
Return	Additional fees will apply if you want Eckert & Ziegler to take care of the final return of the used product.	
Accessories	GalliaPharm <sup>®</sup> is delivered with Accessories for Elution to setup the GalliaPharm <sup>®</sup> for usage. The set contains i.a. tubes with three defined lengths to suit the local situation (refer to the SmPC for further details).	
		*To keep the pharmaceutical status it is mandatory to only use the sterile ultranure

\*To keep the pharmaceutical status it is mandatory to only use the sterile ultrapure 0,1 mol/l hydrochloric acid provided by Eckert & Ziegler for elution of GalliaPharm\*.

#### Marketing authorization holder:

Eckert & Ziegler Radiopharma GmbH, Robert-Rössle-Str. 10, 13125 Berlin, Germany. Name of medicinal product: GalliaPharm 0,74–1,85 GBq radionuclide generator. Active substance: germanium (<sup>68</sup>Ge) chloride as mother nuclide, gallium (<sup>68</sup>Ga) chloride as daughter nuclide. Excipients: column (matrix) titanium dioxide, hydrochloric acid. 0,1 mol/1 Indications: Not for direct use in patients. For in vitro radiolabelling of carrier molecules for diagnostic imaging via positron emission tomography (PET). Contraindications: Hypersensitivity against the active ingredient or the excipients. Side effects: no side effects known. Warnings: radioactive, handle in accordance with radiation protection requirements. Prescription only.

### Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Strasse 10 13125 Berlin Germany Phone: +49 30 941084 280 Fax: +49 30 941084 470

radiopharma@ezag.de www.radiopharma.com